ObjectiveTo evaluate the clinical features of hyperuricemia (HUA) and relationship between serum uric acid (SUA) and metabolic syndrome (MS) in adults.MethodsData were gathered from medical examination among adults age ≥ 20 years,and totally 18 862 subjects were analyzed in this study.ResultsThe prevalence of HUA was 14.8％ (2788/18 862).The rate was 18.4％( 1926/10 445) in men,10.2％ (862/8417) in women.The prevalence of HUA was increased with age,there was significant difference among different age (P =0.000),the rate in men was higher than that in women (P ＜ 0.01 or ＜0.05 ).Compared with normal SUA Patients,the levels of body mass index(BMI),systolic blood pressure (SBP),diastolic blood pressure (DBP),total cholesterol (TC),triacylglycerol (TG) and lowdensity lipid cholesterol(LDL-C) were markedly elevated (P ＜0.01 or ＜0.05),and the level of highdensity lipid cholesterol (HDL-C) was markedly decreased in HUA patients (P ＜0.05).Stepwise regression analysis showed that BMI,SBP,DBP,fasting plasma glucose (FPG),TG,HDL-C were the independent correlation factor of SUA.The incidence of hypertension,over weight/obesity,dyslipidosis,hyperglycosemia and MS in HUA patients [24.1％ (672/2788),36.2％ (1009/2788),31.2％ (870/2788),18.0％ (502/2788),20.8％(580/2788) ] was significantly higher than that in normal SUA patients [ 18.2％ (2925/16 074),26.4％(4244/16 074),22.0％(3536/16 074),15.00(2411/16 074),17.0％(2733/16 074),P＜ 0.01 ].The level of SUA in patients with MS [ (342.3 ± 64.2 ) μ mol/L ] was higher than that of those without MS[ (319.3 ± 67.1 )μ mol/L,P =0.000].ConclusionsThe prevalence of HUA is increased with age.Multiple factors of dysbolism are clustered in subjects with HUA.There is correlation between SUA and MS.

Objective To investigate the effects of weight-loss intervention on metabolic indicators in over-weight or obesity adults.MethodsA total of 116 over-weight or obese adults entered into this study from March 2008 to December 2009.The participants were divided into three groups by age.Each group received 6 months'weight-loss intervention.Body mass index(BMI),body fat rate,blood pressure,fasting blood glucose(FBG),oral glucose tolerance test(OGTY)2 h blood glucose,serum triglyceride(TG),total cholesterol(TC),high-density lipoprotein cholesterol(HDL-C),and low-density lipoprotein cholesterol (LDL-C)were measured before and after the intervention.The data were analyzed using t test.Results After the intervention,BMI,FBG,TG,and LDL-C were significantly decreased while HDL Was significantly increased in each group(P＜0.05).Body fat rate,systolic blood pressure,diastolic blood pressure and OGTT 2 h blood glucose were significantly reduced in the young and middle-aged groups(P＜0.05),however,there Was not significant difference in the older-age group.ConclusionsWeight-loss intervention may be effective in improving physical and metabolic indicators in adults with over-weight and obesity and reducing the risk of obesity-related diseases.

The relationship between subclinical hypothyroidism (SCH) and the components of metabolic syndrome (MS) was explored.A total of 2 252 subjects aged 20 to 79 years from medical examination were identified.The prevalence of SCH was 4.88％.The rate of 7.30％ in female was markedly higher than 2.17％ in male(P＜0.01).The highest SCH prevalence in adults was in the ≥70 years old group.The prevalence of SCH in female was increased with age(P＜0.01).Compared with the euthyroid group,body mass index,triglyceride,and low density lipoprotein-cholesterol were significantly elevated (P＜0.05),while high density lipoprotein-cholesterol was significantly decreased in SCH group(P＜0.05).The incidences of hypertension,dyslipidosis,and MS in SCH group were significantly higher than those in euthyroid group(P＜0.05 or P＜0.01) ; Serum TSH in the MS group was higher than that in the Non-MS group[(2.43 ± 1.55 vs 2.21 ± 1.48) mU/L,P＜0.01].The incidence of SCH in MS group was significantly higher than that in the Non-MS group (7.69％ vs 4.25％,P＜0.05).The prevalence of SCH in women was increased with age.Multiple factors of dysbolism were clustered in subjects with SCH.There is a correlation between SCH and MS.

Objective To investigate the association between obesity and benign prostate hyperplasia (BPH).Methods A total of 253 men (>40 year old) with no obesity related diseases were selected.Medical history,height,body weight,waist circumference (WC),body fat ratio,blood pressure,fasting blood glucose,blood lipid and prostate ultrasound were evaluated.The participants were then assigned to the normal group (body mass index 18.5 to 23.9 kg/m2),overweight group (24.0 to 27.9 kg/m2) and obesity group (≥28 kg/m2).The subjects were also divided into the normal group (WC<85 cm) and abdominal obesity group (WC≥85 cm) or normal group (body fat ratio≤25%) and excessive body fat ratio group (>25%).Prostate volume was analyzed in each group.Results The prostate volume was significantly different between the normal body mass index group and overweight or obesity groups,normal WC group and abdominal obesity group,and normal body fat ratio group and excessive body fat ratio group.The prostate volume was increased in individuals with higher body mass index,WC and body fat ratio.Of those with body mass index≥24 kg/m2 and normal WC or body fat ratio,the incidence of BPH was not significantly increased.Conclusion Obesity may be a risk factor for BPH; individuals with increased WC and body fat ratio may have a higher risk of BPH.

Objective To stuay the serum levels of sCD40L,hsCRP,ICAM-1 and VCAM-1,and the expression of CD40L of the CD4+T cells in patients withacute coronary syndrome(ACS),and to explore the relationship between CD40L and inflammatory factors and the effects of CD40/CD40L on ACS.Method Thirty-two coronary heart disease patients without history of other discernible systemic disease and medicine of steroids or immunosuppressants taken were divided into acute myocardial infarction group(AMI,n=11),unstable angina pectoris group(USP,n=14)and stable angina pectoris group(SAP,n=7).The control group was composed of eight healthy volunteers(CON group).Theexpression of CD40L Was determined by flow cytometry(FCM).Serum sCD40L.ICAM-1 and VCAM-1 were determined by using ELISA.The serum hsCRP was assayed by using immunoturbidimetry.Data were analyzed with SPSS 11.0 software for windows.Results The expression percentage(%)of CD40L of the CD4+T cells,and the serum levels of sCD40L,hsCRP,ICAM-1 and VCAM-1were sifnificantly higher in patients of AMI group than those in patients of other groups(P＜0.05 or P＜0.01).Similarly,those biomarkers in patients of UAP group were usually higher than those in patients of CON or SAP groups(P＜0.05).There Was a positive correlation between the expression of CD40L and the serum level of VCAM-1 in paients of AMI group(P＜0.05),and likewise,a positive correlation also existed between the serum level of sCD40L and other factors,hsCRP,ICAM-1 as well as VCAM-1,in patients of AMI group(P＜0.05).Conclusions The enhanced expression of CD40L of the CD4+T cells and high serum level of sCD40L are present in patients with acute coronary syndrome.The hsCRP,ICAM-1 and VCAM-1 play roles in the pathogenesis of ACS,and they have correlation with enhanced expression of CD40L and high serum level of sCD40L.Therefore,CD40L and sCD40L may be used as indicators of risk in coronary heart disease.

We produced and identified the monoclonal antibodies against Brucella melitensis U‐lipoprotein OMP19 .A DNA fragment coding omp19 of Brucella melitensis was amplified by PCR ,and inserted into the vector of pET‐30a(+ ) ,the result‐ant recombinant plasmid ,which we designated as pET‐30a(+ )/omp19 .We then transformed the plasmid into BL21(DE3) competent cells for the expression of the OMP19 protein .After induction with different concentrations of IPTG ,the colleted cells were analyzed by SDS‐PAGE ,and then OMP19 monoclonal antibodies were prepared through hybridoma technology . These mAbs were tested to reactivity to rOMP19 and nature membrance proteins (NMP) of Brucella melitensis by Western blot and IEST .We successfully constructed an expression vector of pET 30a(+ )/omp19 .An IPTG‐induced expression of the OMP19 protein (19 kDa in molecular weight) was demonstrated by SDS‐PAGE .The fusion protein existed in the form of solu‐ble ,and the OMP19 protein of high purity could be obtained by Ni‐NTA .Western blot assay showed that the refolded protein could be recognized by the anti‐serum against Brucella melitensis .Twenty‐three mAbs to OMP19 was produced in which 91 .30% were IgG1 ,twenty‐two (95 .65% ) mAbs could recognize nature OMP19 protein ,and eighteen (78 .26% ) mAbs could recognize NMP ,four mAbs could react with Brucella melitensis .The protein maintained good immunogenicity and twenty‐three mAbs were obtained ,which we believe provides a good protein candidate for the immunological research .

As one of the hallmarks of cancer, metabolic reprogramming leads to cancer progression, and targeting glycolytic enzymes could be useful strategies for cancer therapy. By screening a small molecule library consisting of 1320 FDA-approved drugs, we found that penfluridol, an antipsychotic drug used to treat schizophrenia, could inhibit glycolysis and induce apoptosis in esophageal squamous cell carcinoma (ESCC). Gene profiling and Ingenuity Pathway Analysis suggested the important role of AMPK in action mechanism of penfluridol. By using drug affinity responsive target stability (DARTS) technology and proteomics, we identified phosphofructokinase, liver type (PFKL), a key enzyme in glycolysis, as a direct target of penfluridol. Penfluridol could not exhibit its anticancer property in PFKL-deficient cancer cells, illustrating that PFKL is essential for the bioactivity of penfluridol. High PFKL expression is correlated with advanced stages and poor survival of ESCC patients, and silencing of PFKL significantly suppressed tumor growth. Mechanistically, direct binding of penfluridol and PFKL inhibits glucose consumption, lactate and ATP production, leads to nuclear translocation of FOXO3a and subsequent transcriptional activation of BIM in an AMPK-dependent manner. Taken together, PFKL is a potential prognostic biomarker and therapeutic target in ESCC, and penfluridol may be a new therapeutic option for management of this lethal disease.